MUCUS RELIEF- guaifenesin tablet SDA Laboratories, Inc.

Active ingredient (in each caplet)

Guaifenesin 400 mg

Purpose

Expectorant

Uses

• helps loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive to rid the bronchial passageways of bothersome mucus

Warnings

Ask a doctor before use if you have

- persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema
- cough accompanied by excessive phlegm (mucus)

Stop use and ask a doctor if

• cough lasts more than 7 days or comes back

• cough occurs with fever, rash or persistent headache. These could be signs of a serious illness.

If pregnant or breast feeding, ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

- take with full glass of water
- not intended for use in children under 12 years of age

| Adults and children 12 years of age and over | take 1 caplet, every 4 hours, while symptoms persist do not exceed 6 doses in 24 hours |
|--|---|
| Children under 12 years of age | do not use |

Other information

- **Tamper Evident:**do not use if imprinted safety seal under cap is broken or missing.
- store at room temperature 15°-30°C (59°-86°F)

Inactive ingredients:

cellulose, magnesium stearate, maltodextrin, povidone, silica, stearic acid.

Questions or comments?

1-203-861-0005

Manufactured for:

SDA Laboratories, Inc.

New York, NY

PRINCIPAL DISPLAY PANEL



MUCUS RELIEF

guaifenesin tablet

| guaifenes in tablet | | | | | | | |
|--|----------------|--------------|--------------------------|---------|----------|--|--|
| | | | | | | | |
| Product Information | | | | | | | |
| Product Type | HUMAN OTC DRUG | Item Code (S | ource) | NDC:664 | 24-001 | | |
| Route of Administration | ORAL | | | | | | |
| | | | | | | | |
| Active Ingradient/Active | Maiaty | | | | | | |
| Active Ingredient/Active Moiety | | | | | | | |
| Ingredient Name | | | Basis of Strength | | Strength | | |
| GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) | | GUAIFENESIN | | 400 mg | | | |
| | | | | | | | |

| Inactive Ingred | ients | | | | |
|-----------------------------|--------------|------------------|----------------------|-------------------------|-----------------------|
| Ingredient Name | | | | | Strength |
| CELLULOSE, MICRO | CRYSTALLI | INE (UNII: OP1R | 32D61U) | | |
| MAGNESIUM STEAR | | | | | |
| MALTODEXTRIN (UNI | I: 7CVR7L44 | 42D) | | | |
| POVIDONE (UNII: FZ989GH94E) | | | | | |
| SILICON DIOXIDE (U | NII: ETJ7Z6> | KBU4) | | | |
| STEARIC ACID (UNII: | 4ELV7Z 65A | P) | | | |
| | | | | | |
| Product Charac | teristics | 5 | | | |
| Color | v | white | Score | 2 pieces | |
| Shape | (| OVAL | · | | 17mm |
| Flavor | | | Imprint Code AP: | | AP;152 |
| Contains | | | | | |
| | | | | | |
| | | | | | |
| Packaging | | | | | |
| # Item Code | Pa | ackage Deso | ription | Marketing Start Date | Marketing End Date |
| | 00 in 1 BOT | TTLE; Type 0: No | ot a Combination | 07/01/2025 | |
| | | | | | |
| | | | | | |
| • 01 P | oforma | tion | | | |
| Marketing Ir | | | r or Monograph | Markating Start | Markating Fod |
| | | | r or Monograph on | Marketing Start Date | Marketing End Date |

Labeler - SDA Laboratories, Inc. (948067889)

Registrant - SDA Laboratories, Inc. (948067889)

| Establishment | | | | | | |
|-------------------------------|---------|-----------|----------------------------|--|--|--|
| Name | Address | ID/FEI | Business Operations | | | |
| Geri-Care Pharmaceutical Corp | | 611196254 | manufacture(66424-001) | | | |

Revised: 5/2025

U.

SDA Laboratories, Inc.